Catalyst
Slingshot members are tracking this event:
Aduro Biotech (ADRO) to assess Phase 1 results of ADU-741 in treatment of prostate cancer, receive Phase 2 decision, in second half of 2017
- Source Link:
- https://seekingalpha.com/filing/3351398
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ADRO | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 30, 2018
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02625857?term=JNJ+64041809&rank=1
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Adu-741, Phase 1 Data, Phase 2, Prostate Cancer
